201 related articles for article (PubMed ID: 29705976)
1. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
Nakachi K; Konishi M; Ikeda M; Shimada K; Okusaka T; Saiura A; Ishii H; Sugiyama M; Furuse J; Sakamoto H; Shimamura T; Ohta T
Int J Clin Oncol; 2018 Oct; 23(5):894-899. PubMed ID: 29705976
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis.
Yoshida M; Yanagimoto H; Tsugawa D; Akita M; Urade T; Nanno Y; Fukushima K; Gon H; Komatsu S; Asari S; Kido M; Toyama H; Ajiki T; Fukumoto T
Am Surg; 2024 Jun; 90(6):1279-1289. PubMed ID: 38226586
[TBL] [Abstract][Full Text] [Related]
4. S-1 monotherapy in patients with advanced biliary tract cancer.
Sasaki T; Isayama H; Yashima Y; Yagioka H; Kogure H; Arizumi T; Togawa O; Matsubara S; Ito Y; Nakai Y; Sasahira N; Hirano K; Tsujino T; Tada M; Kawabe T; Omata M
Oncology; 2009; 77(1):71-4. PubMed ID: 19556812
[TBL] [Abstract][Full Text] [Related]
5. A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).
Itano O; Takemura Y; Kishida N; Tamagawa E; Shinozaki H; Ikeda K; Urakami H; Ei S; Hayatsu S; Suzuki K; Sakuragawa T; Ishii M; Shito M; Aiura K; Fujisaki H; Takano K; Matsui J; Minagawa T; Shinoda M; Kitago M; Abe Y; Yagi H; Oshima G; Hori S; Kitagawa Y
BMC Cancer; 2020 Jul; 20(1):688. PubMed ID: 32703191
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakamura H; Nakashima A; Sueda T
Ann Surg; 2009 Dec; 250(6):950-6. PubMed ID: 19953713
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of adjuvant chemotherapy with S-1 for colorectal liver metastasis.
Uehara K; Maeda A; Sakamoto E; Hiramatsu K; Takeuchi E; Sakaguchi K; Tojima Y; Takahashi Y; Ebata T; Nagino M
Ann Surg Oncol; 2013 Feb; 20(2):475-81. PubMed ID: 22965575
[TBL] [Abstract][Full Text] [Related]
8. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
[TBL] [Abstract][Full Text] [Related]
9. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
[TBL] [Abstract][Full Text] [Related]
10. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
[TBL] [Abstract][Full Text] [Related]
11. An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
Katayose Y; Ohtsuka H; Kitamura Y; Masuda K; Nakagawa K; Yamamoto K; Yoshida H; Onogawa T; Motoi F; Naitoh T; Rikiyama T; Egawa S; Unno M
Hepatogastroenterology; 2012 May; 59(115):691-5. PubMed ID: 22469710
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
[TBL] [Abstract][Full Text] [Related]
15. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT).
Nakachi K; Konishi M; Ikeda M; Mizusawa J; Eba J; Okusaka T; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2018 Apr; 48(4):392-395. PubMed ID: 29462482
[TBL] [Abstract][Full Text] [Related]
16. Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
Hosoda K; Fukushima K; Shimizu A; Motoyama H; Kubota K; Notake T; Sugenoya S; Hayashi H; Yasukawa K; Kobayashi R; Soejima Y
Oncology; 2021; 99(11):703-712. PubMed ID: 34515195
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer.
Kobayashi S; Ueno M; Sugimori K; Morizane C; Kojima Y; Irie K; Goda Y; Morimoto M; Ohkawa S
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1189-1196. PubMed ID: 29071413
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Nakachi K; Ikeda M; Konishi M; Nomura S; Katayama H; Kataoka T; Todaka A; Yanagimoto H; Morinaga S; Kobayashi S; Shimada K; Takahashi Y; Nakagohri T; Gotoh K; Kamata K; Shimizu Y; Ueno M; Ishii H; Okusaka T; Furuse J;
Lancet; 2023 Jan; 401(10372):195-203. PubMed ID: 36681415
[TBL] [Abstract][Full Text] [Related]
20. A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Koike K
J Chemother; 2019 Sep; 31(5):284-289. PubMed ID: 31179889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
